Business & Finance

NIR Diagnostics announces third quarter net income of $1.3 million

Published in Medical Letter on the CDC and FDA, January 7th, 2007

NIR Diagnostics Inc. (NID) announced financial and operational results for the third quarter, recording a net income of $1,323,000 ($0.04 per share) compared with a net loss of $524,000 ($0.02 per share) for the three-month period ended September 30, 2005.

"The business development activity conducted over the past eighteen months, including the U.S. Food & Drug Administration clearance for HemoNIR, continues to pay dividends as awareness grows among potential partners of the multiple applications for our light-based technology," said Duncan MacIntyre, president, CEO and executive vice chairman of NIR Diagnostics.

Our chief priority in the coming...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry